Abstract:Abstract Background Biomarkers can be of help to understand critical illness and to identify and stratify sepsis. Adrenomedullin is a vasoactive hormone, with reported prognostic and potentially therapeutic value in sepsis. The primary aim of this study was to investigate the association of circulating bioactive adrenomedullin (bio-ADM) levels at intensive care unit (ICU) admission with mortality in sepsis patients and in a general ICU population. Secondary aims included the association of bio-ADM with organ failure and the ability of bio-ADM to identify sepsis. Methods In this retrospective observational study, adult patients admitted to one of four ICUs during 2016 had admission bio-ADM levels analysed. Age-adjusted odds ratios (OR) with 95% CI for log-2 transformed bio-ADM, and Youden’s index derived cut-offs were calculated. The primary outcome was 30-day mortality, and secondary outcomes included the need for organ support and the ability to identify sepsis. Results Bio-ADM in 1867 consecutive patients were analysed; 632 patients fulfilled the sepsis-3 criteria of whom 267 had septic shock. The median bio-ADM in the entire ICU population was 40 pg/mL, 74 pg/mL in sepsis patients, 107 pg/mL in septic shock and 29 pg/mL in non-septic patients. The association of elevated bio-ADM and mortality in sepsis patients and the ICU population resulted in ORs of 1.23 (95% CI 1.07–1.41) and 1.22 (95% CI 1.12–1.32), respectively. The association with mortality remained after additional adjustment for lactate in sepsis patients. Elevated bio-ADM was associated with an increased need for dialysis with ORs of 2.28 (95% CI 2.01–2.59) and 1.97 (95% CI 1.64–2.36) for the ICU population and sepsis patients, respectively, and with increased need of vasopressors, OR 1.33 (95% CI 1.23–1.42) (95% CI 1.17–1.50) for both populations. Sepsis was identified with an OR of 1.78 (95% CI 1.64–1.94) for bio-ADM, after additional adjustment for severity of disease. A bio-ADM cut-off of 70 pg/mL differentiated between survivors and non-survivors in sepsis, but a Youden’s index derived threshold of 108 pg/mL performed better. Conclusions Admission bio-ADM is associated with 30-day mortality and organ failure in sepsis patients as well as in a general ICU population. Bio-ADM may be a morbidity-independent sepsis biomarker.

Bio‐adrenomedullin as a marker of congestion in patients with new‐onset and worsening heart failure

Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients hospitalized for acute heart failure: Data from STRONG‐HF

Bioactive adrenomedullin as a marker of congestion and disease progression in patients with a systemic right ventricle

Adrenomedullin in heart failure: pathophysiology and therapeutic application

Pro‐adrenomedullin associates with congestion in acute heart failure patients

Unlocking the potential of biomarkers: The promise of adrenomedullin and its precursors in diagnosing and assessing heart failure

Biomarkers for heart failure: small molecules with high clinical relevance

Activity of the adrenomedullin system to personalise post-discharge diuretic treatment in acute heart failure

Changes of Plasma Adrenomedullin and Proadrenomedullin N-terminal 20 Peptide Concentrations in Patients with Heart Failure.

Pro-adrenomedullin in Acute Decompensation of Liver Cirrhosis: Relationship with Acute-on-chronic Liver Failure and Short-Term Survival.

Circulating Biologically Active Adrenomedullin (bio-ADM) Predicts Hemodynamic Support Requirement and Mortality During Sepsis

Elevated Circulating Levels of C-reactive Protein and Adrenomedullin in Patients with Congestive Heart Failure

Biomarkers of Hemodynamic Congestion in Heart Failure

Circulating bioactive adrenomedullin as a marker of sepsis, septic shock and critical illness

Plasma bioactive adrenomedullin on intensive care unit admission is associated with acute respiratory distress syndrome: an observational study

Adrenomedullin in heart failure: potential therapeutic implications

Adrenomedullin and cardiovascular diseases

Mid-regional pro-adrenomedullin (MR-proADM), a marker of positive fluid balance in critically ill patients: results of the ENVOL study

Residual congestion in acute decompensated heart failure: A novel approach through microvascular imaging of renal circulation

A Focus on the Pathophysiology of Adrenomedullin Expression: Endothelitis and Organ Damage in Severe Viral and Bacterial Infections

Relationship of proadrenomedullin N terminal 20 peptide and the other vasoconstrictive substance in patients with chronic heart failure